Stock BOLT BOLT BIOTHERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Bolt Biotherapeutics, Inc.

Equities

BOLT

US0977021049

Market Closed - Nasdaq
Other stock markets
 21:30:01 03/05/2024 BST 		5-day change 1st Jan Change
1.1 USD 0.00% Intraday chart for Bolt Biotherapeutics, Inc. -0.90% -1.79%
03-21 Bolt Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
03-21 Bolt Biotherapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The company's share price in relation to its net book value makes it look relatively cheap.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company has insufficient levels of profitability.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
BOLT BIOTHERAPEUTICS, INC. Stock Bolt Biotherapeutics, Inc.
-1.79% 41.94M -
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+8.96% 105B
B+
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.43% 104B
B+
ARGENX SE Stock argenx SE
+4.40% 22.94B
B
BIONTECH SE Stock BioNTech SE
-12.15% 22.34B
B+
GENMAB A/S Stock Genmab A/S
-4.36% 19.25B
A-
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.98% 17.08B
A-
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.04% 16.96B
B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.79% 14.16B
C+
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+38.61% 12.63B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. BOLT Stock
  4. Ratings Bolt Biotherapeutics, Inc.